CD274 and hepatocellular carcinoma: To detect the anti-HCC and anti-PD-L1 effects of emodin in vivo, we used an H22 subcutaneous-bearing BALB/c mouse model and treated the mice with emodin (50 mg/kg/day) for 10 consecutive days, as illustrated in Fig. 1D. No difference in body weight between the control and emodin groups was observed (Fig. 1E).